Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma

BACKGROUND: Programmed cell death 1 (PD-1) blockade induces tumor regression in patients with advanced esophageal squamous cell carcinoma (ESCC); however, little is known about the efficacy of PD-1 blockade as neoadjuvant therapy in resectable ESCC. We aim to assess the safety and feasibility of usi...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Weixiong, Xing, Xiangbin, Yeung, Sai-Ching Jim, Wang, Siyu, Chen, Wenfang, Bao, Yong, Wang, Fang, Feng, Shiting, Peng, Fang, Wang, Xiaoyan, Chen, Shuling, He, Minghui, Zhang, Ning, Wang, Honglei, Zeng, Bo, Liu, Zhenguo, Kidane, Biniam, Seder, Christopher W, Koyanagi, Kazuo, Shargall, Yaron, Luo, Honghe, Peng, Sui, Cheng, Chao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8756283/
https://www.ncbi.nlm.nih.gov/pubmed/35022193
http://dx.doi.org/10.1136/jitc-2021-003497

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8756283/
https://www.ncbi.nlm.nih.gov/pubmed/35022193
http://dx.doi.org/10.1136/jitc-2021-003497

Ejemplares similares